Sudarshan Pharma Industries Ratios

Sudarshan Pharma Industries Ltd Ratios

The Sudarshan Pharma Industries Ltd Ratios page provides a complete fundamental analysis of Sudarshan Pharma Industries Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Sudarshan Pharma Industries Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Sudarshan Pharma Industries Ltd (NSE: , BSE: 543828) is currently trading at ₹34.19, with a market capitalization of ₹7.84B. As a major player in the Health technology sector and Pharmaceuticals: major industry, Sudarshan Pharma Industries Ltd remains a key stock for fundamental analysis using Sudarshan Pharma Industries Ltd Ratios.

Sudarshan Pharma Industries Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Sudarshan Pharma Industries Ltd P/E ratio currently stands at 46.34, making it one of the most tracked metrics in Sudarshan Pharma Industries Ltd Ratios.

Historically, the Sudarshan Pharma Industries Ltd P/E ratio has shown strong fluctuations:

• 2024: 46.34
• 2023: 15.66
• 2022: 10.19
• 2021: 0
• 2020: 0

The rising Sudarshan Pharma Industries Ltd P/E ratio indicates increasing investor confidence and premium valuation.

Price to Book Ratio (P/B)

The Sudarshan Pharma Industries Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 5.59.

Historical P/B trend:

• 2024: 5.59
• 2023: 1.60
• 2022: 1.33
• 2021: 0

Sudarshan Pharma Industries Ltd is trading at a premium to its book value, indicating strong market confidence.

Price to Sales Ratio (P/S)

The Sudarshan Pharma Industries Ltd P/S ratio currently stands at 1.46, an important part of Sudarshan Pharma Industries Ltd Ratios for revenue valuation.

Historical P/S ratio:

• 2024: 1.46
• 2023: 0.39
• 2022: 0.16
• 2021: 0

The rising Sudarshan Pharma Industries Ltd P/S ratio indicates improved revenue valuation by investors.

Sudarshan Pharma Industries Ltd Price to Cash Flow Ratio (P/CF)

The Sudarshan Pharma Industries Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 0.

Historical Sudarshan Pharma Industries Ltd Price to Cash Flow Ratio:

• 2024: 0
• 2023: 0
• 2022: 0
• 2021: 0
• 2020: 0

The declining Sudarshan Pharma Industries Ltd Price to Cash Flow Ratio suggests improving cash flow strength.

Sudarshan Pharma Industries Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Sudarshan Pharma Industries Ltd EV currently stands at ₹9.03B, representing the total company valuation including debt.

Historical EV trend:

• 2024: 9.03B
• 2023: 2.78B
• 2022: 880.07M
• 2021: 0

Sudarshan Pharma Industries Ltd enterprise value shows long-term growth, reflecting expansion and market confidence.

EV/EBITDA Ratio

The Sudarshan Pharma Industries Ltd EV/EBITDA ratio is currently 22.26, a key metric in Sudarshan Pharma Industries Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

• 2024: 22.26
• 2023: 12.09
• 2022: 5.82
• 2021: 0

Higher Sudarshan Pharma Industries Ltd EV/EBITDA suggests premium valuation.

Sudarshan Pharma Industries Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Sudarshan Pharma Industries Ltd D/E ratio is currently 1.30, reflecting leverage and financial stability.

Historical D/E:

• 2024: 1.30
• 2023: 0.94
• 2022: 0.34
• 2021: 1.03

Higher D/E ratio indicates rising financial risk.

Return on Equity (ROE %)

The Sudarshan Pharma Industries Ltd ROE currently stands at 13.12%, showing profitability and capital efficiency.

Historical ROE:

• 2024: 13.12
• 2023: 10.77
• 2022: 10.76
• 2021: 20.08

Sudarshan Pharma Industries Ltd maintains stable profitability levels.

Sudarshan Pharma Industries Ltd Ratios Analysis Summary

The Sudarshan Pharma Industries Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Sudarshan Pharma Industries Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Sudarshan Pharma Industries Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.